MA56507A - Nouveaux inhibiteurs d'egfr - Google Patents

Nouveaux inhibiteurs d'egfr

Info

Publication number
MA56507A
MA56507A MA056507A MA56507A MA56507A MA 56507 A MA56507 A MA 56507A MA 056507 A MA056507 A MA 056507A MA 56507 A MA56507 A MA 56507A MA 56507 A MA56507 A MA 56507A
Authority
MA
Morocco
Prior art keywords
egfr inhibitors
new egfr
new
inhibitors
egfr
Prior art date
Application number
MA056507A
Other languages
English (en)
Inventor
Cosimo Dolente
Annick Goergler
David Stephen Hewings
Georg Jaeschke
Bernd Kuhn
Yvonne Alice Nagel
Roger David Norcross
Christa Ulrike Obst-Sander
Antonio Ricci
Daniel Rueher
Sandra Steiner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA56507A publication Critical patent/MA56507A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
MA056507A 2019-06-21 2020-06-19 Nouveaux inhibiteurs d'egfr MA56507A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19181772 2019-06-21

Publications (1)

Publication Number Publication Date
MA56507A true MA56507A (fr) 2022-04-27

Family

ID=67001684

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056507A MA56507A (fr) 2019-06-21 2020-06-19 Nouveaux inhibiteurs d'egfr

Country Status (20)

Country Link
US (2) US20220315591A1 (fr)
EP (2) EP3986567B1 (fr)
JP (2) JP7530390B2 (fr)
KR (1) KR20220024096A (fr)
CN (2) CN113993590B (fr)
AR (2) AR121167A1 (fr)
AU (1) AU2020296933A1 (fr)
BR (1) BR112021024810A2 (fr)
CA (1) CA3139171A1 (fr)
CL (1) CL2021003373A1 (fr)
CO (1) CO2021016967A2 (fr)
CR (1) CR20210614A (fr)
IL (1) IL287806A (fr)
MA (1) MA56507A (fr)
MX (1) MX2021015889A (fr)
PE (1) PE20220807A1 (fr)
PH (1) PH12021553018A1 (fr)
TW (2) TW202115073A (fr)
WO (2) WO2020254546A1 (fr)
ZA (1) ZA202108775B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA56507A (fr) * 2019-06-21 2022-04-27 Hoffmann La Roche Nouveaux inhibiteurs d'egfr
UA129328C2 (uk) * 2019-06-21 2025-03-19 Ф. Хоффманн-Ля Рош Аг Інгібітор egfr для лікування раку
CN120398836A (zh) 2019-11-11 2025-08-01 达纳-法伯癌症研究所股份有限公司 变构egfr抑制剂及其使用方法
JP2023551769A (ja) 2020-12-01 2023-12-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規インダゾール誘導体
EP4255908A1 (fr) * 2020-12-01 2023-10-11 F. Hoffmann-La Roche AG Nouveaux dérivés d'indazole acétylène
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024229406A1 (fr) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Polythérapie pour une maladie ou un trouble lié à ras
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110212078A1 (en) 2008-06-25 2011-09-01 Reddy Panduranga Adulla P Synthesis and use of heterocyclic antibacterial agents
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
BR112017024481B1 (pt) 2015-05-14 2020-11-17 The Wistar Institute Of Anatomy And Biology composto inibidor de ebna1, composição farmacêutica compreendendo dito composto e usos terapêuticos do mesmo
CA2987914C (fr) 2015-06-30 2022-09-13 Dana-Farber Cancer Institute, Inc. Inhibiteurs d'egfr et methodes d'utilisation de ceux-ci
WO2018220149A1 (fr) * 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Composés
BR112020026450A2 (pt) * 2018-06-29 2021-03-23 F. Hoffmann-La Roche Ag Compostos de fórmula i
MA56507A (fr) * 2019-06-21 2022-04-27 Hoffmann La Roche Nouveaux inhibiteurs d'egfr
UA129328C2 (uk) 2019-06-21 2025-03-19 Ф. Хоффманн-Ля Рош Аг Інгібітор egfr для лікування раку
WO2020254544A1 (fr) * 2019-06-21 2020-12-24 F. Hoffmann-La Roche Ag Nouveaux inhibiteurs d'egfr

Also Published As

Publication number Publication date
CN113993591A (zh) 2022-01-28
EP3986566A1 (fr) 2022-04-27
PE20220807A1 (es) 2022-05-20
KR20220024096A (ko) 2022-03-03
CO2021016967A2 (es) 2022-01-17
EP3986566B1 (fr) 2023-08-30
JP2022537771A (ja) 2022-08-29
MX2021015889A (es) 2022-02-03
AU2020296933A1 (en) 2021-12-02
US20220112199A1 (en) 2022-04-14
IL287806A (en) 2022-01-01
AR121167A1 (es) 2022-04-27
TW202115070A (zh) 2021-04-16
AR119207A1 (es) 2021-12-01
ZA202108775B (en) 2022-09-28
US20220315591A1 (en) 2022-10-06
EP3986567A1 (fr) 2022-04-27
EP3986567B1 (fr) 2023-08-30
CA3139171A1 (fr) 2020-12-24
JP2022537772A (ja) 2022-08-29
WO2020254547A1 (fr) 2020-12-24
JP7561779B2 (ja) 2024-10-04
CR20210614A (es) 2022-02-11
CN113993590B (zh) 2024-08-23
CL2021003373A1 (es) 2022-10-07
EP3986567C0 (fr) 2023-08-30
EP3986566C0 (fr) 2023-08-30
TW202115073A (zh) 2021-04-16
CN113993590A (zh) 2022-01-28
WO2020254546A1 (fr) 2020-12-24
JP7530390B2 (ja) 2024-08-07
BR112021024810A2 (pt) 2022-01-25
PH12021553018A1 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
MA56507A (fr) Nouveaux inhibiteurs d'egfr
EP4007752C0 (fr) Inhibiteurs de kif18a
EP4007756C0 (fr) Inhibiteurs de kif18a
MA51616A (fr) Inhibiteurs d'adn-pk
EP4007753C0 (fr) Inhibiteurs de kif18a
EP4197538A4 (fr) Inhibiteur du récepteur du facteur de croissance épidermique
EP3833739A4 (fr) Souche d'akkermansia muciniphila
EP4003212A4 (fr) Marqueur de repère
EP3852762A4 (fr) Nouveaux inhibiteurs de l'egfr quinazoline
EP3906029A4 (fr) Inhibiteurs de l'interaction ménine-mll
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
DK4051688T3 (da) Cd73-hæmmere
EP3828822C0 (fr) Génie civil
EP3919491A4 (fr) Inhibiteur d'akt
EP3938358A4 (fr) Inhibiteurs de rad51
EP3980011C0 (fr) Inhibiteurs de sarm1
EP4076664C0 (fr) Inhibiteurs d' egfr
MA53648A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
EP3742771C0 (fr) Notification m2m sm-sr à sm-dp
EP4030778A4 (fr) Casque d'écoute
EP3814324A4 (fr) Inhibiteurs de la cathepsine c
EP3986565C0 (fr) Nouveaux inhibiteurs de l'egfr
EP4076665C0 (fr) Inhibiteurs d' egfr
EP4037794C0 (fr) Bloc empilable
EP4049824C0 (fr) Moule